Welcome to Innovative Vision Products (IVP) Inc., an intellectual and scientific research group under the guidance of Dr. Mark Babizhayev, Ph.D.
IVP specializes in the fields of ophthalmic and pharmaceutical products, fine cosmetics and nanotechnology.
Our studies have been incorporated into products and protocols for organizations based in the USA, the United Kingdom, Italy, Monaco, Russia and Japan and we are the holders of numerous patents.
Dr. Babizhayev's new book about the problem of
night glare for drivers and how to combat it. Includes details /
explanation of how it contributed to Princess Diana's death in
1997. This book can be purchased from Amazon
In collaboration with a business alliance group from Monaco (as
seen below), we have developed the following biological mimetics of L-carnosine (resistant to enzymatic hydrolysis molecules) for skin care.
1. ALBATIN is a skin whitening agent. As a phosphoric analog of alanine revealed it has interesting melanogenesis inhibiting properties and is a patented aminophosphonic acid, amino-acid derivative.
2. ALISTIN is an antioxidant with broad spectrum of action, it displays a specific affinity for the cell membrane. Its "reverse" effect reduces the lipid hydro peroxides and stops the free-radical propagation. This is a patented Carcinine (decarboxylated carnosine resistant to enzymatic hydrolysis).
3. EXSY-ARL is a detoxifier that protects proteins from damages due to toxic aldehydes and glycation, pollution and stress. This is a patented pseudodipeptide L-Pro-Hist.
4. IMUDILIN restores the immune defense and stimulates the cell metabolism. This is a patented Pseudodipeptide L-Glu-Hist.
Our major interest is in the application of biologically active peptide based compounds and peptidomimetics as novel therapeutic tools. Our special interest is assigned to the peptide-based bioactivating antioxidants and their implication for the treatment of age-related disorders, e.g. having components of oxidative stress in their genesis, including ophthalmic disorders, (for example cataract, glaucoma and macular degeneration).
In cooperation with our Japanese pharmaceutical partner, we have patented carnosinase inhibitor technology, as well as non-hydrolyzed carnosine which shows benefits for the fields of wound care, oncology, respiratory disorders and neuroscience.
We have further revealed and patented the effects of the specific integrin antagonists in the therapeutical management of glaucoma, secondary cataract, angiogenesis and vitreoproliferative disease.
In the fields of nanotechnology, we have formulated original coated materials and a new coating technique for producing medical, surgical and implantable, (especially ophthalmic) devices (such as intraocular lenses with enhanced biocompatibility).
We also provide the patented antioxidant peroxidase enzyme mimic coatings, which significantly improve the biocompatibility of the medical device within the human body, eye and tissues. The coated materials and medical devices acquire anti-oxidant properties useful to block in-vivo free-radical induced peroxidation, which could be responsible for cell membrane damage.
The complications of cataract surgery, such as opacification of posterior lens capsule, corneal and macular edema and intraocular inflammation are avoided in these cases. The coated medical devices provide the properties for preventing the activation of cells induced in apoptosis, inflammatory and foreign body reactions e.g., macrophages, giant cells and fibroblasts, which ordinarily become attached to the material surface of the medical and implantable device.
We also provide the antibacterial coatings which possess new abilities to be used in many applications that can include, (but are not limited to surgical and medical devices), diagnostics, catheters, tubes, sensors, adhesive materials, wound care materials, scar management sheets in patients with burns and during surgery (i.e. breast surgery).
In the Optometry and Ophthalmology fields, we propose for commercialization the diagnostic instrument Halometer medical device and Medical Software, which should be considered as a disability, glare test for vision. Many optometrists and ophthalmologists in the USA and other countries associated with testing of vision and surgery can broadly apply our Halometer diagnostic medical device to the Healthcare service.
This newly formed medical equipment can be focused on the need for cataract screening devices in the developing world to assist the World Health Organization in realizing its aim of eradicating unnecessary blindness.
Our goal is to develop a range of hand held Halometer cataract screening devices that are simple to use and utilize its globally registered IP. The Halometer Medical Device and Medical Software can be applied to follow up the progression or improvement of the cataract, (during the treatment with Can-C� eye drops) and cataract can be measured in a community base.
The Halometer Medical Device and Software can be aimed for optometrists, ophthalmologists and furthermore the Halometer diagnostic devices could also be exploited as the hand-held cataract screening devices for the non-medical user (i.e. health worker/ nurse).
Our route to market is through further targeted and specific clinical trials; utilisation of our medical advisory panel within the ophthalmic community; strategic alliances with a production partner, vision charities and a globally recognised ophthalmic instrument manufacturer/ distributor.
A complete list of all our published references can be viewed in detail by clicking here.
One of our recent discoveries has been the role of the natural di-peptide N-acetylcarnosine in the treatment of human senile cataract. This has aroused a lot of interest because we are the first group to prove that this age related disorder can be improved by an eye-drop, in some cases dispensing with the need for surgery.
Furthermore, cataract can be also effectively treated in canines and pets in the fields of veterinary ophthalmology with our patented formula of N-acetylcarnosine eye drops.
Other than senile cataract, N-acetylcarnosine may have other clinical benefits. The unique and patented N-acetylcarnosine lubricant eye drops formula of Can-C� could also provide beneficial results with the following eye-disorders:
Open-angle primary glaucoma
Computer vision syndrome
Dry eye syndrome
Vitreous opacities and lesions
Complications of diabetes mellitus and other systemic diseases
Contact lens difficulties, particularly with soft contact lenses
(Not only do the lubricants in the Can-C N-acetylcarnosine eye-drop help to make wearing contact lenses more comfortable, but n-acetylcarnosine is also believed to reduce the build up of lactic acid in the eye, thus enabling the lens to be left safely in the eye for longer)
New IVP Development and Proposal for Partnering and Alliance
Telomere attrition and heightened oxidative stress induced by cigarette smoking . Developed nutrition formulas of non-hydrolized carnosine and carcinine supplements offer great opportunities for innovative therapeutic strategies to attenuate naturally accelerated aging and the risk of disease associated with smoking : can we have safer cigarettes ?
Details available here
IVP is a market intelligence company- from our patented research we promote our inventions worldwide through distributors, licencees and joint ventures. Currently, we have developed the worldwide patented N-acetylcarnosine ophthalmic product- this is now registered as the CE marked medical device in all countries of the EU and we have out-licenced an anti-glaucoma pharmaceutical product to a pharmaceutical company.